Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model

被引：0

作者：

F. Dahooee Balooch

S. J. Fatemi

M. Iranmanesh

机构：

[1] Shahid Bahonar University of Kerman,Department of Chemistry, Faculty of Sciences

[2] Islamic Azad University,Department of Chemistry, Faculty of Sciences

来源：

BioMetals | 2014年 / 27卷

关键词：

Lead toxicity; Chelation therapy; Deferasirox; Deferiprone; Rats;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In order to investigate the capability of two chelators deferasirox (DFX or ICL670) and deferiprone (L1) in removing lead from the body, the present research was performed. Two does levels of 40 and 80 mg/kg body weight of lead (II) chloride was given to rats as biological model for 45 days. After 45 days, some toxicity symptoms were observed in rats such as loss of hair and weight, appearance of red dots around eyes, weakness and irritability. After lead application, chelation therapy with DFX and L1 as mono and combined (DFX, L1 and DFX + L1) was done for 10 days. After chelation therapy, lead level in different tissues reduced. The combined chelation therapy results showed that these chelators are able to remove lead from the body and toxicity symptoms decreased. The combined therapy results (DFX + L1) show higher efficacy and lower toxicity compared to single therapies.

引用

页码：89 / 95

页数：6

共 50 条

[41] Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.
Lal, Ashutosh
Sweeters, Nancy
Herz, Matt
Foote, Dru
Neumayr, Lynne
Kurio, Greg
Harmatz, Paul R.
Vichinsky, Elliott P.
BLOOD, 2009, 114 (22) : 798 - 798
[42] COMPARISON OF IRON CHELATION EFFECTS OF DEFEROXAMINE, DEFERASIROX, AND COMBINATION OF DEFEROXAMINE AND DEFERIPRONE ON LIVER AND CARDIAC T2*MRI IN THALASSEMIA MAIOR
Ansari, S.
Abadi, G. Miri Ali
Azarkeivan, A.
HAEMATOLOGICA, 2015, 100 : 595 - 595
[43] Urinary iron excretion in young thalassemic patients receivina combined chelation treatment with deferoxamine and deferiprone
Christoforidis, Athanasios
Zevgaridou, Eleni
Tsatra, Ioanna
Perifanis, Vassilios
Vlachaki, Efthimia
Papassotiriou, Ioannis
Apostolakou, Filia
Athanassiou-Metaxa, Miranda
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (09) : 598 - 601
[44] Combined pulmonary toxicity of diethyldithiocarbamate and lead (II) oxide in rats
Tátrai, E
Náray, M
Brózik, M
Adamis, Z
Ungváry, G
JOURNAL OF APPLIED TOXICOLOGY, 1998, 18 (01) : 33 - 37
[45] Combined Chelation Therapy with Deferoxamine and Deferiprone in β-Thalassemia Major: Compliance and Opinions of Young Thalassemic Patients
Hatzipantelis, Emmanuel S.
Karasmanis, Konstantinos
Perifanis, Vassilios
Vlachaki, Efthimia
Tziomalos, Konstantinos
Economou, Marina
HEMOGLOBIN, 2014, 38 (02) : 111 - 114
[46] Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone
Timoshnikov, Viktor A.
Kichigina, Lilia A.
Selyutina, Olga Yu.
Polyakov, Nikolay E.
Kontoghiorghes, George J.
MOLECULES, 2021, 26 (16):
[47] CHELATION IN METAL INTOXICATION .37. EFFICACY OF COMBINED CHELATION IN LEAD-INTOXICATION
TANDON, SK
SINGH, S
JAIN, VK
CHEMICAL RESEARCH IN TOXICOLOGY, 1994, 7 (05) : 585 - 589
[48] Ethical issues and risk/benefit assessment of iron chelation therapy: Advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox
Kontoghiorghes, George J.
HEMOGLOBIN, 2008, 32 (1-2) : 1 - 15
[49] Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone
Telfer, Paul T.
Warburton, Fiona
Christou, Soteroula
Hadjigavriel, Michael
Sitarou, Maria
Kolnagou, Anita
Angastiniotis, Michael
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1777 - 1778
[50] A Study of the Electrocatalytic Oxidation of Deferiprone and Deferasirox on Nanoshells of NaCo[Fe(CN)6]-Applied to Sensing in Pharmaceuticals and Biological Fluids
Sattarahmady, N.
Heli, H.
SENSOR LETTERS, 2012, 10 (3-4) : 794 - 805

← 1 2 3 4 5 →